12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AVP-786: Phase I data

Data from 36 healthy volunteers in the first stage of a double-blind, crossover Phase I trial showed that AVP-786 plus low-dose quinidine had a comparable pharmacokinetic, safety and tolerability profile to that of AVP-923, a combination product containing dextromethorphan and a higher dose of quinidine (10 mg) than that given with AVP-786. Avanir said AVP-786 and AVP-923 contained the same amount of dextromethorphan in the trial, but declined to disclose the actual dose. The second stage of the trial, which has...

Read the full 392 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >